Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Griffin P. Rodgers, MD, MACP
Researcher Director
National Institute of Diabetes
and Digestive and Kidney Diseases
Building 31, Room 9A52
31 Center Drive
Bethesda, Maryland, United States
Dr. Griffin Rodgers, Director of the National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases, is an accomplished clinician, researcher, and mentor, and is a role model.
His research interests include genetic diseases: sickle cell anemia, thalassemia, red cell enzymopathies; clinical evaluation of disease severity; treatment, including pharmacological alteration of gene expression and stem cell transplantation; molecular genetics of human hemoglobins; gene expression and differentiation in erythroid cells in normal and perturbed hematopoietic states; pharmacological alteration of gene expression; molecular genetics of myleodysplastic and myleoproliferative syndromes; hematopoiesis; role of inducible and stochastic factors; hematopoietic stem cell plasticity; identification of early markers of lineage-specific differentiation; the development of novel gene therapy strategies and their targeted application in cord blood hematopoietic stem cells.
As a research investigator, Dr. Rodgers is widely recognized for his contributions to the development of hydroxyurea, the first effective—and now FDA approved—therapy for sickle cell anemia.
Representative Publications:
Allogeneic hematopoietic stem-cell transplantation for sickle cell disease
HbA2 : biology, clinical relevance and a possible target for ameliorating sickle cell disease
Hemolytic anemia-associated pulmonary hypertension in sickle cell disease
+myBinderRelated Content
-
A Developmental Examination of Pain Among Youth with Sickle Cell DiseaseIntroduction: Sickle cell disease (SCD)...
-
UC Davis Health, Department of PediatricsThe Section of Pediatric Hematology/Onco...
-
Society of Pediatric Psychology Fall Virtual ConferenceSeptember 29, 2023 | 10 a.m. to 5 p.m. E...
-
High mortality among children with sickle cell anemia and overt stroke who discontinue blood transfusion after trans...BACKGROUND: Chronic blood transfusion is...
-
Donna J. Ezell, RNDonna is the Clinical Director at Arkans...
-
Alecia Nero, MDA hematology specialist at UT Southweste...
-
Today’s Faces of Sickle Cell Disease: Swee Lay Thein, MB, BS, FRCP, FRCPath, DScSwee Lay Thein was educated in both Mala...
